Clinical Trials Browser

methanesulfonic acid × 30 days × Clear all

NCT03728335 2026-05-20

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute